| 000 | 02242nam a22002777a 4500 | ||
|---|---|---|---|
| 001 | 20241012101614.0 | ||
| 003 | OCoLC | ||
| 005 | 20241012102025.0 | ||
| 008 | 241012b |||||||| |||| 00| 0 eng d | ||
| 010 | _a2018951636 | ||
| 020 | _a978-3-319-93529-4 | ||
| 020 | _a978-3-319-93530-0 (eBook) | ||
| 040 | _cddc | ||
| 041 | _aEnglish | ||
| 082 | _a616.994 D"AN | ||
| 100 | _qSandra P. D’Angelo | ||
| 245 | _a Immunotherapy of Sarcoma | ||
| 260 |
_aDepartment of Sarcoma Medical Oncology Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York USA | _bSpringer International Publishing AG, part of Springer Nature | _c2019 |
||
| 300 | _a150 Pages | ||
| 300 | _aIncludes References | ||
| 520 | _aThis book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients. | ||
| 600 | _xImmunology, Medical / Clinical Medicine, Medical / Immunology, Medical / Oncology / General, Oncology, Immunotherapy, Sarcoma -- Immunotherapy. | ||
| 700 | _qSeth M. Pollack | ||
| 856 | _u https://doi.org/10.1007/978-3-319-93530-0 | ||
| 942 |
_2ddc _cEB _n0 |
||
| 999 |
_c29144 _d29144 |
||